Katalin Keltai
0000-0002-8294-9062
4 papers found
Refreshing results…
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline
Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design and Participants’ Baseline Characteristics
Missing publications? Search for publications with a matching author name.